EA002384B1 - Композиция, включающая 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-дион - Google Patents

Композиция, включающая 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-дион Download PDF

Info

Publication number
EA002384B1
EA002384B1 EA199901116A EA199901116A EA002384B1 EA 002384 B1 EA002384 B1 EA 002384B1 EA 199901116 A EA199901116 A EA 199901116A EA 199901116 A EA199901116 A EA 199901116A EA 002384 B1 EA002384 B1 EA 002384B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutically acceptable
compound
composition
acceptable form
acceptable carrier
Prior art date
Application number
EA199901116A
Other languages
English (en)
Russian (ru)
Other versions
EA199901116A1 (ru
Inventor
Джай Пэйтел
Хамиш Росс
Робин Прайс
Джеффри Роджер Грэнетт
Original Assignee
Смитклайн Бичам Плс
Смитклайн Бичам Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Смитклайн Бичам Плс, Смитклайн Бичам Корпорейшн filed Critical Смитклайн Бичам Плс
Publication of EA199901116A1 publication Critical patent/EA199901116A1/ru
Publication of EA002384B1 publication Critical patent/EA002384B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
EA199901116A 1997-06-05 1998-06-02 Композиция, включающая 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-дион EA002384B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition
PCT/EP1998/003478 WO1998055122A1 (en) 1997-06-05 1998-06-02 Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Publications (2)

Publication Number Publication Date
EA199901116A1 EA199901116A1 (ru) 2000-06-26
EA002384B1 true EA002384B1 (ru) 2002-04-25

Family

ID=26311662

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199901116A EA002384B1 (ru) 1997-06-05 1998-06-02 Композиция, включающая 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-дион

Country Status (29)

Country Link
EP (1) EP0998284A1 (ja)
JP (1) JP2001521553A (ja)
KR (1) KR20010013410A (ja)
CN (3) CN1526391A (ja)
AP (1) AP1214A (ja)
AR (2) AR008198A1 (ja)
AU (1) AU8215098A (ja)
BG (1) BG104048A (ja)
BR (1) BR9810405A (ja)
CA (2) CA2333352A1 (ja)
CO (1) CO4940400A1 (ja)
DZ (1) DZ2510A1 (ja)
EA (1) EA002384B1 (ja)
GB (1) GB9711683D0 (ja)
HU (1) HUP0004070A3 (ja)
ID (1) ID24264A (ja)
IL (1) IL133074A0 (ja)
MX (1) MXPA99011322A (ja)
NO (2) NO995938L (ja)
NZ (2) NZ523725A (ja)
OA (1) OA11306A (ja)
PE (1) PE78899A1 (ja)
PL (1) PL337201A1 (ja)
SK (1) SK164899A3 (ja)
TR (2) TR199902963T2 (ja)
TW (1) TW570797B (ja)
UY (1) UY25032A1 (ja)
WO (1) WO1998055122A1 (ja)
ZA (2) ZA984826B (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE246191T1 (de) 1999-04-23 2003-08-15 Smithkline Beecham Plc Polymorph von 5-(4-(2-(n-methyl-n-(2- pyrdyl)amino)äthoxy)benzyl)thiazolidin-2,4-dion maleinsäuresalz
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
KR100744359B1 (ko) 1999-04-23 2007-07-30 스미스클라인비이참피이엘시이 티아졸리딘디온 유도체 및 항당뇨병제로서 그의 용도
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP1854794A1 (en) * 2006-05-09 2007-11-14 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306228A1 (en) * 1987-09-04 1989-03-08 Beecham Group Plc Substituted thiazolidinedione derivatives
WO1994005659A1 (en) * 1992-09-05 1994-03-17 Smithkline Beecham Plc Substituted thiazolidinedione derivatives
WO1995021608A1 (en) * 1994-02-10 1995-08-17 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
WO1997005875A2 (en) * 1995-08-10 1997-02-20 Warner-Lambert Company A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO1997018811A1 (en) * 1995-11-17 1997-05-29 Warner-Lambert Company A method of treating myotonic dystrophy
EP0796618A1 (en) * 1996-03-18 1997-09-24 Sankyo Company Limited Treatment and prophylaxis of pancreatitis
WO1998002159A1 (en) * 1996-07-12 1998-01-22 Smithkline Beecham Plc Novel treatment of leptine resistance

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306228A1 (en) * 1987-09-04 1989-03-08 Beecham Group Plc Substituted thiazolidinedione derivatives
WO1994005659A1 (en) * 1992-09-05 1994-03-17 Smithkline Beecham Plc Substituted thiazolidinedione derivatives
WO1995021608A1 (en) * 1994-02-10 1995-08-17 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
WO1997005875A2 (en) * 1995-08-10 1997-02-20 Warner-Lambert Company A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO1997018811A1 (en) * 1995-11-17 1997-05-29 Warner-Lambert Company A method of treating myotonic dystrophy
EP0796618A1 (en) * 1996-03-18 1997-09-24 Sankyo Company Limited Treatment and prophylaxis of pancreatitis
WO1998002159A1 (en) * 1996-07-12 1998-01-22 Smithkline Beecham Plc Novel treatment of leptine resistance

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"R&D FOCUS DRUG NEWS" DIALOG FILE SUPPLIER: FILE 445 R&D FOCUS; ACCESSION NUMBERS 16402 AND 14818, 5 May 1997 - 10 March 1997, XP002082979, see the whole document *
"ROSIGLITAZONE SMITHKLINE BEECHAM CLINICAL DATA", STN FILE SUPPLIER: DRUGNL: ACCESSION NUMBER 1391 & R&D FOCUS DRUG NEWS, 27 April 1998, XP002082989, see the whole document *
"THE PINK SHEET", DIALOG FILE SUPPLIER: FILE 187:F-D-C REPORTS; ACCESSION NUMBER 600160005, vol. 60, no. Issue 16, 20 April 1998, XP002082978, see the whole document *
BERGER J. ET AL: "THIAZOLIOINEDIONES PRODUCE A CONFORMATIONAL CHANGE IN PEROXISOMAL PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA: BINDING AND ACTIVATION CORRELATE WITH ANTIDIABETIC ACTIONS IN DB/DB MICE", ENDOCRINOLOGY, vol. 137, no. 10, October 1996, pages 4189-4195, XP000613643 *

Also Published As

Publication number Publication date
NO995938L (no) 2000-02-02
ZA9811572B (en) 1999-07-22
AP9901696A0 (en) 1999-12-31
AU8215098A (en) 1998-12-21
NZ523725A (en) 2004-09-24
TR199902963T2 (xx) 2000-02-21
CN1526391A (zh) 2004-09-08
CA2292629C (en) 2004-01-06
CN1259050A (zh) 2000-07-05
CN1112926C (zh) 2003-07-02
PE78899A1 (es) 1999-10-22
EP0998284A1 (en) 2000-05-10
NO20040738L (no) 2000-02-02
WO1998055122A1 (en) 1998-12-10
AP1214A (en) 2003-10-08
CN1430959A (zh) 2003-07-23
GB9711683D0 (en) 1997-08-06
BR9810405A (pt) 2000-08-29
SK164899A3 (en) 2000-11-07
CO4940400A1 (es) 2000-07-24
ZA984826B (en) 1999-08-03
JP2001521553A (ja) 2001-11-06
OA11306A (en) 2003-10-22
CA2333352A1 (en) 1998-12-10
TR200002790T2 (tr) 2001-11-21
ID24264A (id) 2000-07-13
EA199901116A1 (ru) 2000-06-26
PL337201A1 (en) 2000-08-14
DZ2510A1 (fr) 2003-01-25
BG104048A (bg) 2000-07-31
NZ513922A (en) 2001-09-28
KR20010013410A (ko) 2001-02-26
MXPA99011322A (es) 2004-12-02
UY25032A1 (es) 1998-11-26
CA2292629A1 (en) 1998-12-10
HUP0004070A2 (hu) 2002-02-28
NO995938D0 (no) 1999-12-03
IL133074A0 (en) 2001-03-19
HUP0004070A3 (en) 2002-03-28
AR008198A1 (es) 1999-12-29
AR015120A1 (es) 2001-04-18
TW570797B (en) 2004-01-11

Similar Documents

Publication Publication Date Title
CZ298469B6 (cs) Farmaceutický prostredek obsahující 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidin-2,4-dion a metformin, a lécivo pro lécení diabetesmellitus
EA002384B1 (ru) Композиция, включающая 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-дион
TW467913B (en) Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt and its preparation
EA004260B1 (ru) Гидрат соли малеиновой кислоты 5-[4-[2-(n-метил-n-(2-пиридил)амино) этокси]бензил]тиазолидин-2,4-диона в качестве фармацевтического препарата
SK179399A3 (en) Use of insulin sensitiser and an insulin
US20020177612A1 (en) Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dione
TW586926B (en) A pharmaceutical composition for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal
DE69837089T2 (de) Behandlung der diabetes mit thiazolidindion und sulfonylharnstoff
KR20010110791A (ko) 티아졸리딘디온 유도체 및 그의 당뇨병약으로서의 용도
BG103966A (bg) Лечение на диабет с тиазолидиндион и инхибитор наалфа глюкозидазата
BG65428B1 (bg) Тиазолидиндионово производно, метод за получаването му, фармацевтичен състав и използването му катоантидиабетик
MXPA99012065A (en) Treatment of diabetes with rosiglitazone and insulin
CZ432299A3 (cs) Kompozice obsahující 5-[4-[2-(N-methyl-N-(2- pyridyI)amino)ethoxy]benzyl]thiazolidin-2,4-dion
JPWO2002028398A1 (ja) 糖尿病治療用組成物
AU9513401A (en) Composition comprising 5-(4-(2-(N-methyl-N-2-pyridyl) amino)ethoxy)benzyl)thiazolidine-2,4-dione
NZ518076A (en) 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM)
HU226960B1 (en) Combination of a dioxothiazolidine and metformin, and pharmaceutical compositions containing the same for the treatment of diabetes
MXPA99012098A (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU